Nature

Errors in cell division stopped by an atypical cyclin-dependent kinase

An organism grows and repairs its body using a form of cell division known as mitosis. To divide, a cell must replicate the chromosomes, which carry the DNA (the instructions needed to build the body) ...
Business Wire

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Business Wire

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.
CU Boulder News & Events

MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells (Science Signalling 2025)

[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
ascopubs.org

A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.

A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors. This is an ASCO Meeting Abstract from ...